NCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
Clinical Trials
11 trialsNCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT04852887 2026-03-03
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT05827081 2026-03-02
Adjuvant WIDER
Novartis
Phase 3 Recruiting
NCT06507618 2026-02-24
POWER II
University of Virginia
Phase 3 Recruiting
NCT07019363 2026-01-21
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Fudan University
Phase 3 Recruiting
NCT07190443 2025-09-29
AURA
Japanese Foundation for Cancer Research
Phase 3 Recruiting
NCT06680921 2025-09-22
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05512364 2025-08-19
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
NCT05952557 2025-06-19
CAMBRIA-2
AstraZeneca
Phase 3 Recruiting
NCT05891093 2024-02-08
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
Phase 3 Recruiting